Tags

Type your tag names separated by a space and hit enter

How beneficiaries fare under the new Medicare drug bill.
Issue Brief (Commonw Fund) 2004; (730):1-16IB

Abstract

The Medicare Prescription Drug Improvement and Modernization Act (MMA) provides the largest benefit expansion in Medicare's history while enacting major changes to the program's structure. Offering $410 billion in new drug benefits will certainly help many beneficiaries now struggling with the costs of prescriptions, particularly those with low incomes. It is difficult to determine, however, whether beneficiaries will be better off in the long run. The drug benefits will not grow with the needs of beneficiaries, and other changes that prove to be unworkable or that place some beneficiaries at risk will create added costs. In the meantime, favorable treatment of private plans will create new inequities. Additional legislation and carefully crafted regulations could mitigate a number of these issues; in the meantime, they will require close scrutiny.

Authors+Show Affiliations

American Institutes for Research, USA. mmoon@air.org

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15176395

Citation

Moon, Marilyn. "How Beneficiaries Fare Under the New Medicare Drug Bill." Issue Brief (Commonwealth Fund), 2004, pp. 1-16.
Moon M. How beneficiaries fare under the new Medicare drug bill. Issue Brief (Commonw Fund). 2004.
Moon, M. (2004). How beneficiaries fare under the new Medicare drug bill. Issue Brief (Commonwealth Fund), (730), pp. 1-16.
Moon M. How Beneficiaries Fare Under the New Medicare Drug Bill. Issue Brief (Commonw Fund). 2004;(730)1-16. PubMed PMID: 15176395.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - How beneficiaries fare under the new Medicare drug bill. A1 - Moon,Marilyn, PY - 2004/6/5/pubmed PY - 2004/7/9/medline PY - 2004/6/5/entrez SP - 1 EP - 16 JF - Issue brief (Commonwealth Fund) JO - Issue Brief (Commonw Fund) IS - 730 N2 - The Medicare Prescription Drug Improvement and Modernization Act (MMA) provides the largest benefit expansion in Medicare's history while enacting major changes to the program's structure. Offering $410 billion in new drug benefits will certainly help many beneficiaries now struggling with the costs of prescriptions, particularly those with low incomes. It is difficult to determine, however, whether beneficiaries will be better off in the long run. The drug benefits will not grow with the needs of beneficiaries, and other changes that prove to be unworkable or that place some beneficiaries at risk will create added costs. In the meantime, favorable treatment of private plans will create new inequities. Additional legislation and carefully crafted regulations could mitigate a number of these issues; in the meantime, they will require close scrutiny. SN - 1558-6847 UR - https://www.unboundmedicine.com/medline/citation/15176395/How_beneficiaries_fare_under_the_new_Medicare_drug_bill_ L2 - https://medlineplus.gov/medicare.html DB - PRIME DP - Unbound Medicine ER -